Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

@article{Gordin2004HepatotoxicityOR,
  title={Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?},
  author={Fred M. Gordin and David L. Cohn and John P. Matts and Richard E. Chaisson and Richard J. O'Brien},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2004},
  volume={39 4},
  pages={561-5}
}
BACKGROUND In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI). After the release of new guidelines, the Centers for Disease Control and Prevention received reports of severe hepatotoxicity associated with the use of the RZ regimen for the treatment of LTBI in the general… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Hepatic safety of antibiotics used in primary care

The Journal of antimicrobial chemotherapy • 2011

New approaches to the treatment of latent tuberculosis.

Seminars in respiratory and critical care medicine • 2008
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease • 2002
View 1 Excerpt

ceptability of short - course rifampin and pyrazinamide treatment of latent tuberculosis among jail inmates

RE Chaisson, J Armstrong, J Stafford, J Golub
Chest • 2001

Similar Papers

Loading similar papers…